Merck 2026 Guidance Falls Short After Q4 Beat
Merck 2026 Guidance came in below estimates after a Q4 beat, citing Januvia patent expirations and Cidara spending, pressuring shares and earnings.
KEY TAKEAWAYS
- Merck topped Q4 estimates driven by strong Keytruda demand.
- Full-year 2026 guidance came in below Wall Street consensus and forecast slower earnings growth.
- Management cited Januvia patent expirations and acquisition spending as primary 2026 headwinds.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Merck & Co. on Feb. 3, 2026 reported fourth-quarter results that topped estimates, driven by strong demand for its cancer immunotherapy Keytruda. However, the company’s full-year 2026 guidance came in below Wall Street expectations, citing patent expirations on Januvia and acquisition spending as key headwinds.
Fourth-Quarter Results and Drivers
Merck’s fourth-quarter earnings per share and revenue exceeded estimates, supported by robust sales of Keytruda and contributions from several newer therapies. These recent product launches helped diversify revenue across multiple therapeutic areas.
2026 Guidance and Headwinds
The company forecast slower earnings growth in 2026, reflecting the anticipated impact of patent expirations and acquisition costs. Merck identified the loss of patent exclusivity on Januvia, a diabetes treatment, as a significant revenue risk. It also flagged accelerated generic competition across affected medicines as a greater threat to revenue than many analysts expect.
Merck is executing the acquisition of Cidara Therapeutics, and acquisition spending is factored into the guidance, weighing on earnings growth. While Keytruda demand remains strong, management indicated its growth will not fully offset revenue declines from patent expirations and acquisition-related expenses reflected in that guidance.
